Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 8/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 8/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17099452 | 0.87 | CYP4F2 (0.53) | CYP4F2CYP4A11TBXAS1CYP2C19GPR84 | |
| SCHEMBL10257161 | 0.87 | CYP4F2 (0.53) | CYP4F2CYP4A11TBXAS1CYP2C19GPR84 | |
| SCHEMBL11226563 | 0.84 | CYP4F2 (0.50) | CYP4F2CYP4A11TBXAS1CYP2C19GPR84 | |
| SCHEMBL22399923 | 0.83 | CYP4F2 (0.59) | CYP4F2CYP4A11TBXAS1CYP2C19GPR84 | |
| SCHEMBL28119855 | 0.81 | CYP4F2 (0.58) | CYP4F2CYP4A11TBXAS1CYP2C19GPR84 | |
| SCHEMBL8432121 | 0.81 | CYP4F2 (0.58) | CYP4F2CYP4A11TBXAS1CYP2C19GPR84 | |
| SCHEMBL798204 | 0.80 | TBXAS1 (0.45) | CYP4F2CYP4A11TBXAS1CYP2C19 | |
| SCHEMBL797992 | 0.80 | TBXAS1 (0.45) | CYP4F2CYP4A11TBXAS1CYP2C19 | |
| SCHEMBL798344 | 0.80 | TBXAS1 (0.45) | CYP4F2CYP4A11TBXAS1CYP2C19 | |
| SCHEMBL798200 | 0.80 | TBXAS1 (0.45) | CYP4F2CYP4A11TBXAS1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | CYP4F2 20/4885CYP4A11 2/4885TBXAS1 379/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | CYP4F2 20/4885CYP4A11 2/4885TBXAS1 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.